Company Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 10:36:03 2024-05-21 am EDT			5-day change	1st Jan Change
3.64 ^USD	-1.36%		-6.67%	+19.40%

May. 03	Aileron Therapeutics Closes Direct Offering of Shares, Warrants	MT
May. 01	Transcript : Aileron Therapeutics, Inc. - Special Call

Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.

Number of employees: 15

Managers	Title	Age	Since
Brian Windsor CEO	Chief Executive Officer	57	23-10-30
David Annis CTO	Chief Tech/Sci/R&D Officer	51	07-10-31
Manuel Alves Aivado BRD	Director/Board Member	53	14-08-31
Liz Melone IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Josef H. Von Rickenbach CHM	Chairman	68	19-06-18
Alan Musso BRD	Director/Board Member	62	23-10-30
Brian Windsor CEO	Chief Executive Officer	57	23-10-30
Reinhard Ambros BRD	Director/Board Member	67	13-05-31
Manuel Alves Aivado BRD	Director/Board Member	53	14-08-31
William Fairey BRD	Director/Board Member	60	23-10-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,589,576	20,619,682 ( 95.51 %)	0	95.51 %
Stock B	0	24,610	0	0

Name	Equities	%	Valuation
University of Texas Investment Management Co. 10.55 %	1,790,142	10.55 %	9 M $
Alerce Investment Management LP 4.893 %	830,466	4.893 %	4 M $
Nantahala Capital Management LLC 1.502 %	255,000	1.502 %	1 M $
Senvest Management LLC 1.360 %	230,895	1.360 %	1 M $
Geode Capital Management LLC 0.4110 %	69,759	0.4110 %	348 795 $
Sigma Planning Corp. 0.4006 %	67,985	0.4006 %	339 925 $
Renaissance Technologies LLC 0.2655 %	45,064	0.2655 %	225 320 $
Vanguard Group, Inc. (Subfiler) 0.2375 %	40,314	0.2375 %	201 570 $
Gagnon Securities LLC 0.2236 %	37,947	0.2236 %	189 735 $
RBC Capital Markets LLC 0.2121 %	36,000	0.2121 %	180 000 $

Aileron Therapeutics, Inc.

12407 North Mopac Expressway Suite 250

78758, Austin

http://www.aileronrx.com

address Aileron Therapeutics, Inc.(ALRN)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.69 USD

Average target price

19 USD

Spread / Average Target

+414.91%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AILERON THERAPEUTICS, INC.	+19.40%	78.01M
VERTEX PHARMACEUTICALS INCORPORATED	+8.42%	115B
REGENERON PHARMACEUTICALS, INC.	+13.01%	107B
BIONTECH SE	-13.75%	22.31B
ARGENX SE	-3.73%	21.6B
BEIGENE, LTD.	-6.00%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.57%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.85%	12.37B
LEGEND BIOTECH CORPORATION	-27.36%	8.28B

Bio Therapeutic Drugs